Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatology Other
    Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort - (BMJ)
    Zoledronic Acid Improves Bone Loss Associated With Adjuvant AI Therapy in Postmenopausal Breast Cancer Patients: Presented at SABCS - (DGDispatch)
    Ibandronate Offers Pain Relief With Renal Safety in Women With Breast Cancer, Metastatic Bone Disease: Presented at SABCS - (DGDispatch)
    Severe Joint Pain in Multiple Areas Associated With Increased Risk of Falls in Older Adults - (DGNews)
    Rilonacept Approved in the EU for Cryopyrin-Associated Periodic Syndromes - (DGNews)

    News archive

     Recent webcasts/CME - Rheumatology Other
      Debate: What to do after the TNF Inhibitor Fails?
      Biologic Therapies: Clinical Implications for Rheumatologists, Gastroenterologists, Allied Health Practitioners
      Faculty Feud: Current Concepts in the Pathogenesis and Treatment of Pulmonary Arterial Hypertension
      CSI: PAH Case Study Investigation (CSI) Diagnosis and Management of Pulmonary Arterial Hypertension--Case Review Monograph
      Rheumatology Highlights Report - Post 2009 National Meeting Vasculitis: Pathology, Diagnosis, and Treatment

      Webcasts/CME archive

       Recent cases - Rheumatology Other
        Pancreatitis And Atypical Kawasaki Disease
        Efficacy Of Thalidomide In A Girl With Inflammatory Calcinosis, A Severe Complication Of Juvenile Dermatomyositis
        A Patient With Pfeifer-Weber-Christian Disease - Successful Therapy With Cyclosporin A: Case Report
        Idiopathic Sclerosing Mesenteritis In Paediatrics: Report Of A Successfully Treated Case And A Review Of Literature
        IgA Nephropathy in Two Patients with Sjögren's Syndrome: One with Concomitant Autoimmune Hepatitis

        Cases archive
          




        my personal edition > rheumatology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Uveitis Flares in Ankylosing Spondylitis Patients Reduced With Adalimumab: Presented at ACR

        By Ed Susman

        BOSTON, MA -- November 12, 2007 -- The incidence of uveitis flares -- a common visual complication in patients with ankylosing spondylitis -- was markedly reduced when patients were being treated with adalimumab. That's according to research presented here on November 8 at the 71st annual meeting of the American College of Rheumatology (ACR).

        While on treatment, the painful and disabling disorder flared about 7.4 times per 100 patient-years -- less than half the recorded 15 flares per 100 patient-years when the individuals with ankylosing spondylitis were not on the biologic drug.

        "Uveitis is a fairly common and potentially serious complication of ankylosing spondylitis," said Martin Rudwaleit, MD, Rheumatology Consultant, Charité University Hospital, Berlin, Germany. "This study is an example of the research needed to better understand this condition and the impact it has on these patients."

        Dr. Rudwaleit headed the Review of safety and effectiveness witH Adalimumab in Patients with active ankylosing SpOnDYlitis (RHAPSODY) trial, which examined the effectiveness of adalimumab in treating ankylosing spondylitis. The trial recruited 1,250 patients, including 274 with a history of uveitis.

        In the prospective, multinational, open-label trial, adult patients with active ankylosing spondylitis who had insufficient responses to prior nonsteroidal anti-inflammatory drug (NSAID) therapy received open-label adalimumab 40 mg subcutaneously every other week for 12 weeks. Patients with symptomatic uveitis at baseline and/or in the previous year received the same regimen for a total of 20 weeks. Evaluations of treatment effects were measured at weeks 2, 6, 12, and week 20, if applicable.

        The uveitis analysis measured the number of acute flares during treatment with adalimumab both for all patients in the trial and for patients with a history of uveitis.

        Overall, 27 adverse events of uveitis were reported for 25 of the 1,250 patients. Two of the 25 patients experienced an attack of uveitis for the first time. In both patients, the general ankylosing spondylitis disease activity was high at the time of the anterior uveitis episode.

        "Adalimumab had a substantial preventive effect on uveitis flares in patients with ankylosing spondylitis," said Dr. Rudwaleit, "even among the patients who had a history of uveitis."

        The study was sponsored by Abbott.


        [Presentation title: Adalimumab Reduces the Incidence of Uveitis Flares in Patients With Ankylosing Spondylitis. Abstract 578]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send